Treatment of COVID-19 during the acute phase in hospitalized patients decreases post-acute sequelae of COVID-19

Badenes Bonet, Diana, 1987-; Caguana Vélez, Oswaldo Antonio; Duran Jordà, Xavier, 1974-; Comas Serrano, Mercè; Posso, Margarita; Admetlló Papiol, Mireia; Herranz Blasco, Anna; Cuadrado Godia, Elisa; Marco Navarro, Ester; Martin Ezquerra, Gemma; Pineiro Aguin, Zenaida; Cumpli Gargallo, Maria Cinta; Gonzalez Garcia, Jose Gregorio; Balcells Vilarnau, Eva, 1967-; Rodríguez Chiaradia, Diego Agustín; Castells, Xavier; Gea Guiral, Joaquim; Horcajada Gallego, Juan Pablo; Villar García, Judit; MAR Post-COVID-19 Unit

Treatment of COVID-19 during the acute phase in hospitalized patients decreases post-acute sequelae of COVID-19

Mostra el registre complet Registre parcial de l'ítem

dc.contributor.author Badenes Bonet, Diana, 1987-
dc.contributor.author Caguana Vélez, Oswaldo Antonio
dc.contributor.author Duran Jordà, Xavier, 1974-
dc.contributor.author Comas Serrano, Mercè
dc.contributor.author Posso, Margarita
dc.contributor.author Admetlló Papiol, Mireia
dc.contributor.author Herranz Blasco, Anna
dc.contributor.author Cuadrado Godia, Elisa
dc.contributor.author Marco Navarro, Ester
dc.contributor.author Martin Ezquerra, Gemma
dc.contributor.author Pineiro Aguin, Zenaida
dc.contributor.author Cumpli Gargallo, Maria Cinta
dc.contributor.author Gonzalez Garcia, Jose Gregorio
dc.contributor.author Balcells Vilarnau, Eva, 1967-
dc.contributor.author Rodríguez Chiaradia, Diego Agustín
dc.contributor.author Castells, Xavier
dc.contributor.author Gea Guiral, Joaquim
dc.contributor.author Horcajada Gallego, Juan Pablo
dc.contributor.author Villar García, Judit
dc.contributor.author MAR Post-COVID-19 Unit
dc.date.accessioned 2023-10-04T06:25:08Z
dc.date.available 2023-10-04T06:25:08Z
dc.date.issued 2023
dc.description.abstract Background: The post-acute sequelae of SARS-CoV-2 (PASC) infection have caused a significant impact on our health system, but there is limited evidence of approved drugs focused on its prevention. Our objective was to identify risk factors that can determine the presence of PASC, with special attention to the treatment received in the acute phase, and to describe the profile of persistent symptoms in a multidisciplinary Post-Coronavirus Disease-19 (COVID-19) Unit. Methods: This one-year prospective observational study included patients following an acute COVID-19 infection, irrespective of whether they required hospital admission. A standardized symptom questionnaire and blood sampling were performed at the first follow-up visit, and demographic and clinical electronic data were collected. We compared subjects with PASC with those who had fully recovered. Multivariate logistic regression was performed to identify factors associated with PASC in hospitalized patients, and Kaplan-Meier curves were used to assess duration of symptoms according to disease severity and treatments received in the acute phase. Results: 1966 patients were evaluated; 1081 had mild disease, 542 moderate and 343 severe; around one third of the subjects had PASC, and were more frequently female, with obesity, asthma, and eosinophilia during acute COVID-19 disease. Patients who received treatment with dexamethasone and remdesivir during the course of the acute illness showed a lower median duration of symptoms, compared with those who received none of these treatments. Conclusion: Treatment with dexamethasone and/or remdesivir may be useful to reduce the impact of PASC secondary to SARS-CoV-2 infection. In addition, we identified female gender, obesity, asthma, and disease severity as risk factors for having PASC.
dc.format.mimetype application/pdf
dc.identifier.citation Badenes Bonet D, Caguana Vélez OA, Duran Jordà X, Comas Serrano M, Posso Rivera M, Admetlló M, Herranz Blasco A, Cuadrado Godia E, Marco Navarro E, Martin Ezquerra G, Pineiro Aguin Z, Cumpli Gargallo MC, Gonzalez Garcia JG, Balcells Vilarnau E, Rodriguez Chiaradia D, Castells X, Gea J, Horcajada JP, Villar-García J; MAR Post-COVID-19 Unit. Treatment of COVID-19 during the acute phase in hospitalized patients decreases post-acute sequelae of COVID-19. J Clin Med. 2023 Jun 20;12(12):4158. DOI: 10.3390/jcm12124158
dc.identifier.doi http://dx.doi.org/10.3390/jcm12124158
dc.identifier.issn 2077-0383
dc.identifier.uri http://hdl.handle.net/10230/58037
dc.language.iso eng
dc.publisher MDPI
dc.relation.ispartof J Clin Med. 2023 Jun 20;12(12):4158
dc.rights © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.rights.uri http://creativecommons.org/licenses/by/4.0/
dc.subject.keyword SARS-CoV-2
dc.subject.keyword Corticosteroids
dc.subject.keyword Long COVID
dc.subject.keyword Post-acute sequelae of COVID-19 (PASC)
dc.subject.keyword Remdesivir
dc.title Treatment of COVID-19 during the acute phase in hospitalized patients decreases post-acute sequelae of COVID-19
dc.type info:eu-repo/semantics/article
dc.type.version info:eu-repo/semantics/publishedVersion

Col·leccions

Articles (Departament de Medicina i Ciències de la Vida)
Articles (Hospital del Mar Research Institute)